Jci_page_head_homepage_01 Jci_page_head_homepage_02
Ki Hoon Han, Mi Kyung Chang, Agnes Boullier, Simone R. Green, Andrew Li, Christopher K. Glass, Oswald Quehenberger
Published in Volume 106, Issue 6
J Clin Invest. 2000; 106(6):793–802 doi:10.1172/JCI10052
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9

Reduction of CCR2 expression in circulating monocytes by BRL49653 in vivo. LDL receptor–deficient mice were placed for 2 and 8 weeks on BRL49653 (20 mg/kg body weight), and the effect on CCR2 expression in circulating monocytes was determined. (a) Analysis of CCR2 protein by flow cytometry. Mononuclear leukocytes were isolated from untreated control (n = 8) and BRL49653-treated (n = 4) animals. The monocyte population was identified with anti-CD80 Ab, stained with phycoerythrin-conjugated anti-CCR2 IgG, and analyzed by flow cytometry. In preliminary experiments it was established that the anti-human CCR2 IgG crossreacted with mouse CCR2. Phycoerythrin-labeled non-specific IgG was used to estimate background fluorescence. (b) Analysis of CCR2 transcripts. The monocytes were purified from mononuclear leukocytes by plating. The levels of CCR2 mRNA in circulating monocytes from control and treated animals were estimated by semiquantitative RT-PCR using 0.5 μg of total RNA. All values shown are normalized to GAPDH. P values were estimated using the unpaired Student’s t test. AP < 0.01; BP < 0.05.